CDK4 and cancer: There may also be a bias created by the fact that 12% of the patients who received 1st-line therapy appeared to respond to ET for more than 5 years, which may indicate that the cohort of patients who received 2nd-line ET + CDK4/6i had more aggressive cancer and, therefore, worse outcomes.